AGA Reading Room
New HCV Tx Works Well for Severe Liver Disease
Contributing Writer, MedPage Today
New therapies safe and effective in patients with decompensated cirrhosis
Treatment using direct-acting antivirals (DAAs) produces good cure rates in chronic hepatitis C (HCV) patients with decompensated liver disease, offering new options for a group that often could not be treated with interferon-based therapy. Successful treatment can slow liver disease progression and may restore lost hepatic function.
Genotype 1 or 4 patients who are ineligible, unable, or unwilling to take ribavirin can use the DAAs alone and increase treatment duration to 24 weeks. Patients with prior sofosbuvir failure should both add ribavirin and extend therapy to 24 weeks....
- Newly Diagnosed
- All FDA Approved Drugs To Treat Hepatitis C
- 2017-HCV Genotypes/Treatment
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Not FDA Approved - Sofosbuvir/Velpatasvir/Voxilaprevir
- Not FDA Approved - Glecaprevir/Pibrentasvir (G/P)
- NOT FDA Approved - MK3 (MK-3682/grazoprevir/ruzasvir1)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- Treating Elderly HCV Patients
- FibroScan® Understanding The Results
- Staging Cirrhosis
- Is There A Natural Way To Improve Liver Fibrosis?